XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company recorded the following revenues for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
ORLADEYO:
U.S.$79,966 $60,849 
Outside of U.S.8,901 7,565 
Total ORLADEYO88,867 68,414 
Other revenues3,894 364 
Total revenues$92,761 $68,778 
ORLADEYO revenues represent total revenues from product sales, collaborative revenues and royalties. Other revenues primarily relate to the Company’s product sales and royalties for peramivir injection (RAPIVAB/RAPIACTA/PERAMIFLU).